-
-
Refugees resettling to the United States and other developed countries frequently suffer from infectious diseases, and can pose diagnostic or therapeutic dilemmas for health care providers in their new homes.
-
This multicenter, randomized, placebo-controlled trial of a synthetic GHRH analogue, tesamorelin (1-44 amino acids from the amino terminal of GHRH with a trans-3-hexenoyl group added to the amino terminal to increase the half-life over native GHRH), randomized 412 patients (86% male) to daily subcutaneous tesamorelin vs placebo for 26 weeks.
-
Sixty-one hospitals in 28 countries participated in a prospective cohort study of hospitalized patients with definite endocarditis.
-
The diagnosis of malaria has traditionally relied upon microscopy. However, microscopic diagnosis is labor intensive and somewhat subjective, and assurance of quality standards can be difficult at best.
-
In this issue: Rosiglitazone (Avandia) implicated in yet another study; Prilosec and Nexium not associated with cardiac events; Anastrozole (Arimidex) shown more effective than tamoxifen for treatment of early-stage breast cancer; antibiotics show no effect on sinusitis; FDA actions.
-
The number, type, and severity of comorbidities are important determinants of diabetes self-care.
-
Patients with mild-to-moderate obstructive sleep apnea (OSA) who were treated with Continuous Positive Airway Pressure (CPAP) experienced an absolute risk reduction in cardiovascular risk compared with those who were not treated.
-
Absent or low testosterone levels in men appear to have a pathogenic role in the development of cardiovascular disease resulting in increased cardiovascular and all-cause mortality and are not simply "markers" for illness or wellness.
-
The FDA has approved, by priority review, the first drug to help manage patients with phenylketonuria (PKU).
